R&D Pipeline

Phase:
Therapy:
Pipeline last updated 29 December 2014
Compound/Indication
Phase123
Semaglutide (NN9535) Type 2 diabetes
LATIN T1D (NN9211) Type 1 diabetes
N8-GP (NN7088) Haemophilia A
N9-GP (NN7999) Haemophilia B
NN8640 Growth disorder
OG217SC (NN9924) Type 2 diabetes
LAI287 (NN1436) Type 1 and 2 diabetes
LAI338 (NN1438) Type 1 and 2 diabetes
OI338GT (NN1953) Type 1 and 2 diabetes
OG987GT (NN9926) Type 2 diabetes
OG987SC (NN9927) Type 2 diabetes
G530L (NN9030) Obesity
NN9838 Obesity
Concizumab (NN7415) Haemophilia A and B